This preliminary descriptive report compares the rates of detecting high- and low-grade prostate cancer in men invited for prostate cancer screening vs
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate Primary endpoints and secondary endpoints for which data are available were met in trial dominated by COVID-19 variants Efficacy demonstrated agai.
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline today announce positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18 years and above, across six countries.
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by COVID-19 variants Efficacy demonstrated against all variants seen in the study, including 75.3%